Zhenya Lindgardt Sells 7,022 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Posted by George Bondi on Sep 13th, 2026

Sera Prognostics, Inc. (NASDAQ:SERA – Get Free Report) CEO Zhenya Lindgardt sold 7,022 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $2.00, for a total value of $14,044.00. Following the completion of the transaction, the chief executive officer owned 837,848 shares in the company, valued at $1,675,696. The trade was a 0.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenya Lindgardt also recently made the following trade(s):

On Tuesday, September 8th, Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total value of $40,278.00.

Sera Prognostics Trading Down 1.0%

Shares of SERA opened at $2.03 on Friday. The company has a market capitalization of $80.08 million, a price-to-earnings ratio of -3.03 and a beta of 0.98. The stock has a 50 day moving average of $2.05 and a 200 day moving average of $2.02. Sera Prognostics, Inc. has a 12 month low of $1.56 and a 12 month high of $3.95.

Sera Prognostics (NASDAQ:SERA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.07 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%. As a group, equities research analysts predict that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

SERA has been the topic of a number of research analyst reports. Craig Hallum assumed coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. Weiss Ratings upgraded shares of Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Check Out Our Latest Report on Sera Prognostics

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Arkadios Wealth Advisors bought a new stake in shares of Sera Prognostics in the first quarter valued at $25,000. Lido Advisors LLC bought a new stake in Sera Prognostics in the 3rd quarter valued at about $68,000. Cetera Investment Advisers purchased a new stake in Sera Prognostics during the fourth quarter valued at about $74,000. Qube Research & Technologies Ltd purchased a new stake in Sera Prognostics during the second quarter valued at about $92,000. Finally, Two Sigma Investments LP bought a new position in Sera Prognostics during the third quarter worth about $97,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.